Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Recruiting 2Active not recruiting 1

Sponsor Class

NIH 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Head & Neck 3

Conditions

Carcinoma, Non-Small-Cell Lung 23Squamous Cell Carcinoma of Head and Neck 10Melanoma 8Lung Neoplasms 8Neoplasms 7Carcinoma 6Skin Neoplasms 5Neoplasm Metastasis 5Carcinoma, Squamous Cell 5Carcinoma, Basal Cell 5Adenocarcinoma 5Mouth Neoplasms 4Head and Neck Neoplasms 4Colonic Neoplasms 4Carcinoma, Renal Cell 4Urinary Bladder Neoplasms 3Sarcoma 3Oropharyngeal Neoplasms 3Laryngeal Neoplasms 3Carcinoma, Merkel Cell 3Breast Neoplasms 3Triple Negative Breast Neoplasms 2Recurrence 2Rectal Neoplasms 2Pancreatic Neoplasms 2Mesothelioma, Malignant 2Hemangiosarcoma 2Colorectal Neoplasms 2Carcinoma, Hepatocellular 2Adrenocortical Carcinoma 2

Interventions

Cisplatin 20Cetuximab 11Carboplatin 9Specimen Handling 8Radiotherapy 8Docetaxel 8Radiotherapy, Intensity-Modulated 7Magnetic Resonance Spectroscopy 71,2-diaminocyclohexaneplatinum II citrate 7Platinum 6Fluorouracil 6pembrolizumab 5Radiation 5toripalimab 4Paclitaxel 4cemiplimab 3X-Rays 3Surgical Procedures, Operative 3Celecoxib 3Biopsy 3130-nm albumin-bound paclitaxel 3Taxes 2Standard of Care 2Radiotherapy, Image-Guided 2Hydroxyurea 2Drug Therapy 2tislelizumab 1sodium thiosulfate 1sargramostim 1sacituzumab govitecan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Laryngeal Neoplasms × cemiplimab × Clear all
NCT07195734 2026-05-19

Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer

National Cancer Institute (NCI)

Phase 2 Recruiting
180 enrolled
Head & Neck

Carcinoma, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT06980038 2026-05-13

Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer

National Cancer Institute (NCI)

Phase 2 Recruiting
44 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Laryngeal Neoplasms, Mouth Neoplasms

NCT04862650 2026-02-10

Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Ohio State University Comprehensive Cancer Center

Phase 2 Active not recruiting
46 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡